Literaturverzeichnis Prof. Dr. med. R. Kimmig Originalarbeiten ...

123.
124.
125.
126.
127.
128.
129.
130.
131.
Fink D, Perucchini D, Lang U, Kimmig R.
Urinary incontinence and descensus genitalis--the silent sickness.
Gynäkol Geburts. Rundsch (2006);46(3):77-8
Hauth EA, Jaeger H, Maderwald S, Stockamp C, Muhler A, Kimmig R, Forsting
M.
Evaluation of quantitative parametic analysis for characterization of breast lesions
in constrast-enhanced MR mammography.
Eur Radiol (2006);29
Kimmig R, Fink D, Lang U.
Organ preservation, multimodal radical tumor therapy and reduction of therapyrelated
morbidity--development of diagnostics and therapy of endometrial
carcinoma.
Gynäkol Geburtsh. Rundsch (2006);46(1-2):1-2
Hahn S, Benson S, Elsenbruch S, Pleger K, Tan S, Mann K, Schedlowski M, van
Halteren WB, Kimmig R, Janssen OE.
Metformin treatment of polycystic ovary syndrome improves health-related qualityof-life,
emotional distress and sexuality.
Hum Reprod (2006);21(7):1925-34
Schmitz KJ, Callies R, Wohlschlaeger J, Kimmig R, Otterbach F, Bohr J, Lee HS,
Takeda A, Schmid KW, Baba HA.
Overexpression of cyclo-oxygenase-2 is an independent predictor of unfavourable
outcome in node-negative breast cancer, but is not associated with protein kinase
B (Akt) and mitogen-activated protein kinase (ERK1/2, p38) activation or with Her-
2/neu signalling pathways.
J Clin Pathol (2006);59(7):685-91
Böing C, Kimmig R.
Fertility-preserving treatment in young women with endometrial cancer.
Gynäkol Geburtsh. Rundsch (2006);46(1-2):25-33
Pfisterer J, Weber B, Reuss A, Kimmig R, du Bois A, Wagner U, Bourgeois H,
Meier W, Costa S, Blohmer JU, Lortholary A, Olbricht S, Stahle A, Jackisch C,
Hardy-Bessard AC, Mobus V, Quaas J, Richter B, Schroder W, Geay JF, Luck HJ,
Kuhn W, Meden H, Nitz U, Pujade-Lauraine E; AGO-OVAR; GINECO.
Randomized phase III trial of topotecan following carboplatin and paclitaxel in firstline
treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of
the AGO-OVAR and GINECO.
J Natl Cancer Inst (2006); 2;98(15):1036-45
Wimberger P., Kasimir-Bauer S, Weck B., Kimmig R.
Antikörpertherapien beim Ovarialkarzinom
Frauenarzt (2006); 10; 920 – 923
Pfisterer J., du Bois A, Sehouli J, Loibl S, Reinartz S, Reuss A, Canzler U, Belau
A, Jackisch C., Kimmig R., Wollschlaeger K, Heilmann V, Hilpert F.
The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer.
A phase I trial of the AGO-OVAR.
Ann Oncol. 2006 Oct;17(10):1568-1577.